Currax Pharmaceuticals (United States)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy

Carel W. le Roux, Nadège Fils‐Aimé, Fernando Camacho et al. · EClinicalMedicine · 2022 · 27 citations · Full text

Extended‐release naltrexone/bupropion and liver health: Pooled, post hoc analysis from four randomized controlled trials

Harpreet S. Bajaj, Melonie Burrows, Jessica Blavignac et al. · Diabetes Obesity and Metabolism · 2020 · 25 citations

Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight

Roger S. McIntyre, Emilia Paron, Melonie Burrows et al. · Journal of Affective Disorders · 2021 · 20 citations · Full text

Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial

Sean Wharton, Peter Yin, Melonie Burrows et al. · International Journal of Obesity · 2021 · 10 citations · Full text